Wednesday, April 24, 2024
4/24/2024
IL-35 inhibits gut microbiota-produced uremic toxin-accelerated endothelial cell activation Chronic kidney disease (CKD) affects 15% of the adult population worldwide. CKD promotes cardiovascular morbidity and mortality. Increased endothelial cell (EC) activation/dysfunction and vascular inflammation play a critical role the development of CKD-accelerated cardiovascular disease (CVD), which begins in the early stages of CKD. New therapies are urgently needed to inhibit EC activation/dysfunction accelerated by CKD. EC dysfunction is associated with reduced nitric oxide (NO) production whereas our new JBC paper showed EC activation features include: 1) increased secretion of cytokines and chemokines; 2) upregulation of EC adhesion molecules; 3) upregulation of additional DAMP receptors; and 4) upregulation of T cell co-stimulation/co-inhibition receptors. Novel strategies targeted at reducing EC activation/dysfunction and vascular inflammation may provide effective treatment in the early stages of CKD. Trimethylamine-N-Oxide (TMAO) is a gut microbiota generated, choline-derived metabolite. TMAO is a newly identified as a uremic toxin, which is strongly elevated in CKD and associated with atherosclerotic CVDs. TMAO induces EC dysfunction and increased vascular inflammation via binding to G-protein coupled receptor, thereby activating mitogen-activated protein kinase and NF-¿B, and increasing circulating cytokines. We and others reported that interleukin-35 (IL-35) is a new and powerful anti-inflammatory cytokine that inhibits various inflammation. Plasma IL-35 levels are increased in CKD patients. Therefore, the central hypothesis of this proposal is that IL-35 suppresses uremic toxin TMAO-induced EC activation/dysfunction and CKD-accelerated vascular inflammation. Therefore, we will examine this hypothesis via following three aims: 1) To determine expression and suppressive function of IL-35/IL-35R subunits in TMAO-induced human aortic ECs (HAECs) and mouse aortic ECs (MRECs) from CKD mice; 2) To determine the molecular mechanisms, by which IL-35 inhibits EC activation via inhibiting mitochondrial reactive oxygen species (mtROS) generation, suppressing caspase-1(casp1) canonical/casp11 non-canonical inflammasome signaling, and inhibiting histone 3 lysine 14 acetylation (H3K14ac) induced EC activation gene expression; and 3) To determine the suppressing roles of two IL-35 subunits (p35, and EBI3) and an IL-35 receptor (IL-35R) subunit (IL12Rß2) in CKD mouse model. The aim 3 will be explored through the use of a novel IL-35 therapy (gain of function) in CKD mouse model, and four loss of function CKD models including p35-/- CKD mice, EBI-3-/- CKD mice, global IL-12Rß2-/- CKD mice and EC-specific IL12Rb2-/- CKD mice to determine the suppressive roles of IL-35 signaling in EC dysfunction and vascular inflammation in CKD. The significance of this proposal is that the success of these studies should have a major impact in the field, and provide novel mechanistic insights into IL-35 in suppressing TMAO-induced EC activation and CKD-accelerated vascular inflammation, which could lead to the potential development of novel therapeutics for CKD-accelerated CVDs.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
